Intervet/Schering-Plough Animal Health recently reported revenue of $669 million for its third quarter ended Sept. 30, a 12 percent decrease compared to $759 million in the year-ago period. The sales decline was primarily due to the overall economic environment, difficult comparisons against the 2008 launch of bluetongue vaccine and back orders on certain products, according to the company, adding that the back orders were due primarily to the ongoing integration of animal health manufacturing practices and quality standards. Year to date, Intervet/Schering-Plough Animal Health reported revenue of $2 billion, a 14 percent decrease compared to $2.3 billion in the year-ago period. Intervet/Schering-Plough Animal Health’s parent company, Schering-Plough, reported net income of $515 million on revenue of $4.5 billion for its third quarter, compared to net income of $614 million on revenue of $4.6 billion in the year-ago period. Year to date, Schering-Plough reported net income of $2 billion on revenue of $13.5 billion, compared to net income of $1.4 billion on revenue of $14.2 billion. <HOME>
